New cell therapy trial targets Hard-to-Treat solid tumors
NCT ID NCT07242417
First seen Nov 21, 2025 · Last updated May 08, 2026 · Updated 16 times
Summary
This early-phase trial is testing a new treatment called TC-G203 for people with advanced solid tumors that have a specific marker (GPC3) and have not responded to standard therapies. The main goal is to find the safest dose and check for side effects. About 30 adults will take part in this study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Email: •••••@•••••
-
GoBroad Healthcare Group
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.